Is NKTR or OMER more profitable?

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Nektar Therapeutics -284.18% -85.40% -39.99% Omeros N/A -102.16% 64.87%

Does the media prefer NKTR or OMER?

In the previous week, Omeros had 5 more articles in the media than Nektar Therapeutics. MarketBeat recorded 7 mentions for Omeros and 2 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.82 beat Omeros' score of 0.57 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Omeros 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OMER or PRGO more profitable?

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Perrigo -43.50% 9.96% 3.90%

Does the media favor OMER or PRGO?

In the previous week, Omeros had 3 more articles in the media than Perrigo. MarketBeat recorded 7 mentions for Omeros and 4 mentions for Perrigo. Perrigo's average media sentiment score of 0.57 beat Omeros' score of 0.57 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PCRX or OMER more profitable?

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Pacira BioSciences 0.70% 10.24% 5.47% Omeros N/A -102.16% 64.87%

Does the media refer more to PCRX or OMER?

In the previous week, Omeros had 5 more articles in the media than Pacira BioSciences. MarketBeat recorded 7 mentions for Omeros and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.94 beat Omeros' score of 0.57 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ASMB or OMER?

In the previous week, Omeros had 5 more articles in the media than Assembly Biosciences. MarketBeat recorded 7 mentions for Omeros and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.94 beat Omeros' score of 0.57 indicating that Assembly Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer OMER or CPIX?

Omeros currently has a consensus target price of $38.00, suggesting a potential upside of 279.62%. Given Omeros' stronger consensus rating and higher possible upside, equities analysts clearly believe Omeros is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor OMER or CPIX?

In the previous week, Omeros had 3 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 7 mentions for Omeros and 4 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.82 beat Omeros' score of 0.57 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cumberland Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Omeros (OMER) Competitors

$10.01 -0.27 (-2.63%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$9.68 -0.33 (-3.29%)

As of 05:10 AM Eastern

Compare

OMER vs. NKTR, PRGO, PCRX, ASMB, and CPIX

Should you buy Omeros stock or one of its competitors? MarketBeat compares Omeros with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omeros include Nektar Therapeutics (NKTR), Perrigo (PRGO), Pacira BioSciences (PCRX), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceuticals" industry.

How does Omeros compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Omeros (NASDAQ:OMER) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Omeros	N/A	-102.16%	64.87%

Omeros has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	41.80	-$164.08M	-$8.42	N/A
Omeros	N/A	N/A	-$3.35M	$0.70	14.30

In the previous week, Omeros had 5 more articles in the media than Nektar Therapeutics. MarketBeat recorded 7 mentions for Omeros and 2 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.82 beat Omeros' score of 0.57 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nektar Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Omeros has a beta of 2.55, indicating that its share price is 155% more volatile than the broader market.

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 10.5% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nektar Therapeutics currently has a consensus price target of $149.63, indicating a potential upside of 119.01%. Omeros has a consensus price target of $38.00, indicating a potential upside of 279.62%. Given Omeros' stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Omeros beats Nektar Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Omeros compare to Perrigo?

Omeros (NASDAQ:OMER) and Perrigo (NYSE:PRGO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Omeros presently has a consensus price target of $38.00, suggesting a potential upside of 279.62%. Perrigo has a consensus price target of $19.33, suggesting a potential upside of 90.20%. Given Omeros' stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

48.8% of Omeros shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Perrigo	-43.50%	9.96%	3.90%

Omeros has a beta of 2.55, meaning that its stock price is 155% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

In the previous week, Omeros had 3 more articles in the media than Perrigo. MarketBeat recorded 7 mentions for Omeros and 4 mentions for Perrigo. Perrigo's average media sentiment score of 0.57 beat Omeros' score of 0.57 indicating that Perrigo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.30
Perrigo	$4.25B	0.33	-$1.43B	-$13.10	N/A

Summary

Omeros beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Omeros compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, Omeros had 5 more articles in the media than Pacira BioSciences. MarketBeat recorded 7 mentions for Omeros and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.94 beat Omeros' score of 0.57 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.38	$7.03M	$0.12	212.83
Omeros	N/A	N/A	-$3.35M	$0.70	14.30

Pacira BioSciences currently has a consensus target price of $29.40, indicating a potential upside of 15.11%. Omeros has a consensus target price of $38.00, indicating a potential upside of 279.62%. Given Omeros' stronger consensus rating and higher probable upside, analysts clearly believe Omeros is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Omeros	N/A	-102.16%	64.87%

Pacira BioSciences has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Omeros has a beta of 2.55, suggesting that its stock price is 155% more volatile than the broader market.

Summary

Pacira BioSciences and Omeros tied by winning 8 of the 16 factors compared between the two stocks.

How does Omeros compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by company insiders. Comparatively, 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Assembly Biosciences has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Omeros has a beta of 2.55, meaning that its stock price is 155% more volatile than the broader market.

In the previous week, Omeros had 5 more articles in the media than Assembly Biosciences. MarketBeat recorded 7 mentions for Omeros and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.94 beat Omeros' score of 0.57 indicating that Assembly Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Assembly Biosciences currently has a consensus price target of $44.00, indicating a potential upside of 63.20%. Omeros has a consensus price target of $38.00, indicating a potential upside of 279.62%. Given Omeros' stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Omeros has lower revenue, but higher earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.93	-$6.12M	-$0.11	N/A
Omeros	N/A	N/A	-$3.35M	$0.70	14.30

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Assembly Biosciences' return on equity of -4.21% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Omeros	N/A	-102.16%	64.87%

Summary

Omeros beats Assembly Biosciences on 12 of the 16 factors compared between the two stocks.

How does Omeros compare to Cumberland Pharmaceuticals?

Omeros (NASDAQ:OMER) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Cumberland Pharmaceuticals has higher revenue and earnings than Omeros. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.30
Cumberland Pharmaceuticals	$44.52M	2.20	-$2.84M	-$0.49	N/A

Omeros has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Cumberland Pharmaceuticals' return on equity of -12.01% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

Omeros currently has a consensus target price of $38.00, suggesting a potential upside of 279.62%. Given Omeros' stronger consensus rating and higher possible upside, equities analysts clearly believe Omeros is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

48.8% of Omeros shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Omeros has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

In the previous week, Omeros had 3 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 7 mentions for Omeros and 4 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.82 beat Omeros' score of 0.57 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cumberland Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omeros beats Cumberland Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Omeros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMER vs. The Competition

Export

Metric	Omeros	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$744.02M	$8.82B	$7.05B	$12.61B
Dividend Yield	N/A	2.54%	2.68%	8.00%
P/E Ratio	14.30	16.09	27.11	24.26
Price / Sales	N/A	7.04	589.14	117.88
Price / Cash	5.49	18.40	29.22	49.36
Price / Book	-5.85	3.57	10.75	6.29
Net Income	-$3.35M	$228.19M	$3.58B	$330.66M
7 Day Performance	-3.10%	-2.31%	-2.10%	-1.35%
1 Month Performance	14.66%	-0.62%	3.29%	-0.64%
1 Year Performance	154.71%	-2.73%	26.32%	19.08%

Omeros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMER Omeros	3.9761 of 5 stars	$10.01 -2.6%	$38.00 +279.6%	+174.2%	$744.02M	N/A	14.30	210	Gap Down
NKTR Nektar Therapeutics	3.1659 of 5 stars	$73.15 +3.0%	$149.63 +104.5%	+173.2%	$2.40B	$55.23M	N/A	220
PRGO Perrigo	3.8332 of 5 stars	$11.10 +0.7%	$19.33 +74.2%	-63.1%	$1.52B	$4.25B	N/A	8,100
PCRX Pacira BioSciences	2.1889 of 5 stars	$25.59 +0.8%	$29.40 +14.9%	+11.5%	$999.04M	$726.41M	213.27	720
ASMB Assembly Biosciences	2.2122 of 5 stars	$28.90 +4.2%	$44.00 +52.2%	+43.8%	$440.86M	$72.30M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMER) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omeros (OMER) Competitors

OMER vs. NKTR, PRGO, PCRX, ASMB, and CPIX

How does Omeros compare to Nektar Therapeutics?

Summary

How does Omeros compare to Perrigo?

Summary

How does Omeros compare to Pacira BioSciences?

Summary

How does Omeros compare to Assembly Biosciences?

Summary

How does Omeros compare to Cumberland Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omeros (OMER) Competitors

OMER vs. NKTR, PRGO, PCRX, ASMB, and CPIX

How does Omeros compare to Nektar Therapeutics?

Is NKTR or OMER more profitable?

Which has preferable valuation and earnings, NKTR or OMER?

Does the media prefer NKTR or OMER?

Which has more volatility and risk, NKTR or OMER?

Do insiders & institutionals hold more shares of NKTR or OMER?

Do analysts prefer NKTR or OMER?

Summary

How does Omeros compare to Perrigo?

Do analysts recommend OMER or PRGO?

Do institutionals & insiders have more ownership in OMER or PRGO?

Is OMER or PRGO more profitable?

Which has more risk & volatility, OMER or PRGO?

Does the media favor OMER or PRGO?

Which has preferable earnings and valuation, OMER or PRGO?

Summary

How does Omeros compare to Pacira BioSciences?

Does the media refer more to PCRX or OMER?

Which has higher valuation & earnings, PCRX or OMER?

Do analysts rate PCRX or OMER?

Do insiders and institutionals believe in PCRX or OMER?

Is PCRX or OMER more profitable?

Which has more volatility and risk, PCRX or OMER?

Summary

How does Omeros compare to Assembly Biosciences?

Do insiders & institutionals have more ownership in ASMB or OMER?

Which has more volatility & risk, ASMB or OMER?

Does the media refer more to ASMB or OMER?

Do analysts prefer ASMB or OMER?

Which has better earnings & valuation, ASMB or OMER?

Is ASMB or OMER more profitable?

Summary

How does Omeros compare to Cumberland Pharmaceuticals?

Which has higher earnings & valuation, OMER or CPIX?

Is OMER or CPIX more profitable?

Do analysts prefer OMER or CPIX?

Do institutionals and insiders hold more shares of OMER or CPIX?

Which has more risk & volatility, OMER or CPIX?

Does the media favor OMER or CPIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools